ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 67 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $190,447,555 | -36.2% | 9,493,896 | -10.2% | 0.02% | -36.0% |
Q2 2023 | $298,365,097 | -2.7% | 10,576,572 | -40.7% | 0.02% | +78.6% |
Q1 2023 | $306,598,634 | +92.5% | 17,825,502 | +125.4% | 0.01% | -12.5% |
Q4 2022 | $159,290,805 | -2.8% | 7,909,176 | +4.5% | 0.02% | -5.9% |
Q3 2022 | $163,958,000 | -25.0% | 7,569,606 | -2.7% | 0.02% | -22.7% |
Q2 2022 | $218,510,000 | -29.8% | 7,776,168 | +15.3% | 0.02% | -12.0% |
Q1 2022 | $311,109,000 | -45.5% | 6,742,694 | -0.8% | 0.02% | -40.5% |
Q4 2021 | $571,257,000 | +26.8% | 6,795,831 | +0.6% | 0.04% | +16.7% |
Q3 2021 | $450,348,000 | +27.1% | 6,757,935 | +1.4% | 0.04% | +28.6% |
Q2 2021 | $354,431,000 | +32.7% | 6,662,225 | +8.2% | 0.03% | +21.7% |
Q1 2021 | $267,111,000 | -15.6% | 6,156,042 | +1.0% | 0.02% | -17.9% |
Q4 2020 | $316,422,000 | +238.7% | 6,092,078 | +113.2% | 0.03% | +211.1% |
Q3 2020 | $93,425,000 | -15.8% | 2,857,920 | +23.7% | 0.01% | -25.0% |
Q2 2020 | $110,972,000 | – | 2,310,946 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |